Products - Metastases | Topic | NICE

Showing 48 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
15 June 2022
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer (TA1150)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 May 2026
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal) (TA1141)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 March 2026
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 February 2026
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 February 2026
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1122)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 January 2026
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA1120)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 January 2026
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
9 July 2026
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 September 2026
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
2 December 2026
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
16 December 2026
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
7 April 2027
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 May 2027
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Suspected cancer update
Status:
In development
Expected publication date:
TBC
Palbociclib with anti-HER2 and endocrine therapies for maintenance treatment of hormone-receptor positive HER2-positive metastatic breast cancer [ID6251]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6436]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Camizestrant as an add-on to a first-line CDK4/6 inhibitor for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation [ID6535]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [ID6677]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab tirumotecan for treating advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma after 2 or more treatment lines [ID6723]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer [ID6734]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tucatinib with trastuzumab and oxaliplatin-based chemotherapy for untreated HER2-positive metastatic or unresectable colorectal cancer [ID6755]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12399]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dabrafenib with trametinib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12398]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC